Earnings calls

Senores Pharma. concall ledger

Every earnings call for SENORES — management tone, guidance, KPIs and promise tracking, quarter by quarter.

SENORES · 3 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 14 May 2026Call held 14 May 2026

SENORES Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹190 cr+66% YoYEBITDA₹62 cr+200% YoYEBITDA Margin32.7%

Revenue (Q4 FY26) ₹190 cr (+66% YoY); EBITDA (Q4 FY26) ₹62 cr (+200% YoY); EBITDA Margin (Q4 FY26) 32.7%. FY26 Revenue reached INR 664 crores, marking a 62% YoY growth.

Read full transcript & analysis

Q2 FY26Published 20 Jan 2026Call held 20 Jan 2026

SENORES Q2 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹175 cr+64% YoYConsolidated EBITDA₹54 cr+86% YoYConsolidated EBITDA Margin30.9%Consolidated PAT₹32 cr+85% YoY

Consolidated Revenue ₹175 cr (+64% YoY); Consolidated EBITDA ₹54 cr (+86% YoY); Consolidated EBITDA Margin 30.9%. Consolidated revenue grew 64% YoY to INR175 crores in Q3 FY26.

Read full transcript & analysis

Q4 FY25Published 24 Jul 2025Call held 24 Jul 2025

SENORES Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹138 cr+72% YoYEBITDA₹34 cr+60% YoYEBITDA Margin24.8%−2% YoYPAT₹21 cr+95% YoY

Revenue ₹138 cr (+72% YoY); EBITDA ₹34 cr (+60% YoY); EBITDA Margin 24.8% (−2% YoY). Consolidated revenue grew by 72% YoY to INR 138 crores.

Read full transcript & analysis